C.
| Comparison | Study number | Patient number | ||||||
|---|---|---|---|---|---|---|---|---|
| Control | 9 | 703 | ||||||
| Abatacept | 2 | 165 | ||||||
| Obinutuzumab | 1 | 63 | ||||||
| Belimumab | 1 | 223 | ||||||
| IL-2 | 1 | 13 | ||||||
| Ocrelizumab | 1 | 148 | ||||||
| Rituximab | 2 | 114 | ||||||
| Anifrolumab | 1 | 51 |
LN, lupus nephritis; SD, standard deviation; IL-2, interleukin-2; CTLA-4, cytotoxic T-lymphocyte antigen 4; CYC, cyclophosphamide; MMF, mycophenolate mofetil.
a
Latin America and Caribbean 60%, Europe and Israel 29%, the USA 11%.
b
Range, mixed.
c
Asian 223 (50%), white 148 (33%), black 61 (14%), American Indian or Alaska Native 10 (2%), and multiple races 4 (1%).
d
Azathioprine, cyclosporine, tacrolimus, leflunomide, thalidomide, or methotrexate.
e
White 51%, African American 41%, Asian 3%, undeclared 3%.
f
Asian 60.6%, white 28.3%, African American 6.1%, other 5.1%.
g
Latin America 42%, Asia 23.1%, Western Europe 12.9%, Eastern Europe 10.5%, the USA and Canada 10.2%, Africa 1.3%.
h
White 26.4%, black 27.8%, Hispanic 40.3%, Asian/Pacific Islander 5.6%.